BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37339636)

  • 1. Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.
    Kim MS; Ra EA; Kweon SH; Seo BA; Ko HS; Oh Y; Lee G
    Cell Stem Cell; 2023 Jul; 30(7):973-986.e11. PubMed ID: 37339636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optogenetic induction of alpha-synuclein aggregation in human dopaminergic neurons to model Parkinson's disease pathology.
    Ra EA; Kim MS; Lee G
    STAR Protoc; 2023 Dec; 4(4):102609. PubMed ID: 37742181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
    Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
    Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
    FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson's disease.
    Shin JY; Lee B; Ham S; Kim JH; Kim H; Kim H; Jo MG; Kim HJ; Park SW; Kweon HS; Kim YJ; Yun SP; Lee Y
    Biomed Pharmacother; 2022 Dec; 156():113908. PubMed ID: 36283223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons.
    Tanudjojo B; Shaikh SS; Fenyi A; Bousset L; Agarwal D; Marsh J; Zois C; Heman-Ackah S; Fischer R; Sims D; Melki R; Tofaris GK
    Nat Commun; 2021 Jun; 12(1):3817. PubMed ID: 34155194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson's disease model.
    Alwani A; Maziarz K; Burda G; Jankowska-Kiełtyka M; Roman A; Łyszczarz G; Er S; Barut J; Barczyk-Woźnicka O; Pyza E; Kreiner G; Nalepa I; Chmielarz P
    Pharmacol Rep; 2023 Dec; 75(6):1474-1487. PubMed ID: 37725330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease.
    Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I
    Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease in a dish - Using stem cells as a molecular tool.
    Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
    Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein pathology is associated with astrocyte senescence in a midbrain organoid model of familial Parkinson's disease.
    Muwanigwa MN; Modamio-Chamarro J; Antony PMA; Gomez-Giro G; Krüger R; Bolognin S; Schwamborn JC
    Mol Cell Neurosci; 2024 Mar; 128():103919. PubMed ID: 38307302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease.
    Arkan S; Ljungberg M; Kirik D; Hansen C
    Neurobiol Dis; 2021 Oct; 158():105477. PubMed ID: 34390836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
    Yang J; Luo S; Zhang J; Yu T; Fu Z; Zheng Y; Xu X; Liu C; Fan M; Zhang Z
    Neurobiol Dis; 2021 Jan; 148():105218. PubMed ID: 33296726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
    Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
    J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.
    Parmasad JA; Ricke KM; Nguyen B; Stykel MG; Buchner-Duby B; Bruce A; Geertsma HM; Lian E; Lengacher NA; Callaghan SM; Joselin A; Tomlinson JJ; Schlossmacher MG; Stanford WL; Ma J; Brundin P; Ryan SD; Rousseaux MWC
    Cell Death Dis; 2024 Apr; 15(4):246. PubMed ID: 38575601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
    Oh Y
    BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.